Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Rhode Island: - Women and Infants Hospital — Providence, Rhode Island
- Kent Hospital — Warwick, Rhode Island
- Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Rhode Island: - Rhode Island Hospital — Providence, Rhode Island
- Women and Infants Hospital — Providence, Rhode Island
- Miriam Hospital — Providence, Rhode Island
- Kent Hospital — Warwick, Rhode Island
- Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Rhode Island: - Rhode Island Hospital — Providence, Rhode Island
- Women and Infants Hospital — Providence, Rhode Island
- Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Rhode Island: - Rhode Island Hospital — Providence, Rhode Island
- Women and Infants Hospital — Providence, Rhode Island
- Kent Hospital — Warwick, Rhode Island
- Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Rhode Island: - Women and Infants Hospital — Providence, Rhode Island
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Rhode Island: - Rhode Island Hospital — Providence, Rhode Island
Phase 2 Recruiting Academic/Other
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in Rhode Island: - Smilow Cancer Hospital Care center at Westerly — Westerly, Rhode Island
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Rhode Island: - Women and Infants Hospital of Rhode Island — Providence, Rhode Island
Phase 2 Recruiting Industry
A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a cyclin dep…
Sponsor: AstraZeneca
NCT ID: NCT07427394
Sites in Rhode Island: - Research Site — East Providence, Rhode Island
Phase 1 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat adva…
Sponsor: AbbVie
NCT ID: NCT06084481
Sites in Rhode Island: - Lifespan Cancer Institute at Rhode Island Hospital /ID# 257693 — Providence, Rhode Island
Recruiting Academic/Other
This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.
Sponsor: Abramson Cancer Center at Penn Medicine
NCT ID: NCT06551116
Sites in Rhode Island: - Smilow Cancer Hospital Care Center — Westerly, Rhode Island